Log in
Registration
Українська
English
Search for:
Home
Online Publication
Current Issue
Issue Archive
Authors
About
Information About the Journal
Focus and Scope
Indexing
For Authors
Submission Guidelines and Requirements
Peer Review
Article Processing Charges
Copyright and Licensing
Policies
Editorial Policy
Plagiarism Policy
Archiving Policy
Policy on the Use of Artificial Intelligence (AI) and AI-Supported Technologies
Open Access
Procedure for the Retraction of Published Articles
Ethical Issues
Publication Ethics
Procedure for Handling Complaints Regarding Ethical Breaches
Privacy Statement
International Standards and Principles of Operation
Organization of anticancer fight
Tumors of the chest cavity
Tumors of abdominal organs
Tumors of skin, soft tissues, bones
Breast tumor
Oncogynecology
Tumors of the head and neck
Oncurology
Oncohematology
Radiation diagnostics, radiation therapy
Experimental studies
Magazine online
All news
Keyword : non-small cell lung cancer
Paradigm reset: modern approaches to lung cancer diagnosis and treatment
Author:Zviahina O.V. Т. 15, №3 (59)
Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/−bevacizumab for the first-line treatment of non-squamous NSCLC: a matching-adjusted indirect comparison
Т. 15, №1 (57)
From theory to practice. The art of lung cancer treatment
Т. 14, №3 (55)
Efficacy of EGFR TKIs of different generations in NSCLC with EGFR mutations: review of clinical studies and our experience
Authors: Kobziev O.I. Boiarskyi O.O. Leonova V.V. Т. 12, № 3-4 (47-48)
Pembrolizumab is first-line treatment for patients with advanced non-small cell lung cancer in both mono and combination regimens
T. 10, № 1-2 (37-38)
Prevalence of
EGFR
gene mutations in Ukrainian patients with locally advanced or metastatic non-small cell lung cancer
Authors: Shparyk Ya.V. Ponomareva O.V. Sokolov V.V. Kobzev O.Y.... T. 10, № 1-2 (37-38)
ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer (review)
Authors: Kolesnik O.P. Shevchenco A.I. Kadzhoian A.V. Kuzmenko V.A.... Т. 8, № 4 (32) 2018
The role of targeted therapy in the treatment of patients with EGFR+ mutations of lung cancer (review)
Authors: Kolesnik O.P. Shevchenco A.I. Kadzhoian A.V. Kuzmenko V.A.... Т. 8, № 3 (31) 2018
Modern approaches to the treatment of inoperable non-small cell lung cancer
Authors: Klimаnоv М.Yu. Sivak L.A. Tarasenko T. Askоlskiy А.В.... №4(24) 2016
Erlotinib efficacy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
Author:Toracica Oncologia Italiana Associazione and Pneumo-Cancerologie de Francais Groupe with collaboration in Group Cancer Lung Spanish №7 (3) 2012
Expression of glicoprotein Pgp-170 by the hemopoietic peripheral blood and bone marrow cells in the CML patients with different response to tyrosine kinase inhibitors therapy
Authors: Perekhrestenko T.P. Gordiyenko A.I. Tretyak N.N. Dyagil I.S.... №5 (1) 2012